CSL BEHRING

Lobbying client · Pennsylvania · filed 2025 to 2026

Biopharmaceutical manufacturer.

$200,000 Reported spend

5 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 5 filings. Everything on this page is grouped by the client's LDA id (68762), not by name.

Firms hired 1

MARSHALL & POPP, LLC $200,000 5 filings

Reported by year 2 years

2026 $110,000 2 filings
2025 $90,000 3 filings

Issues lobbied 2

Pharmacy 5
Trade (domestic/foreign) 5

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 4

Food & Drug Administration (FDA) 4
HOUSE OF REPRESENTATIVES 4
Natl Economic Council (NEC) 4
SENATE 4

Recent filings 5 total

Q2

MARSHALL & POPP, LLC

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $60,000 income · posted Jul 9, 2026

View → Q1

MARSHALL & POPP, LLC

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $50,000 income · posted Apr 17, 2026

View → Q4

MARSHALL & POPP, LLC

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $50,000 income · posted Jan 16, 2026

View → Q3

MARSHALL & POPP, LLC

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $40,000 income · posted Oct 20, 2025

View → RR

MARSHALL & POPP, LLC

3rd Quarter (July 1 - Sep 30) 2025 · posted Sep 17, 2025

View →

Foreign entities disclosed 1

CSL LIMITED Australia named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.